Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Building a Better Covid-19 Antibody Test

ProMIS is harnessing its unique technology platform to develop a more error-free antibody test. Testing has been an Achilles heel of the coronavirus pandemic, but ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) has partnered with Dr. Hans Frykman and the ...
Streetwise Reports | May 7, 2020 |

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |

A ‘Novel’ Investment In Psychedelic-Inspired Medicines

Stockhouse investors are keenly aware of the booming trend in the psychedelic healthcare space…in many ways the new Cannabis 2.0 over the last 12 – 24 months. Capital markets have taken to them en masse – a market now estimated to be in excess of USD$5 billion and expected ...
Dave Jackson | April 16, 2021 |

Triple Threat Canbud Launches New Products Targeting the Hottest Health & Wellness Trends

After its public listing last October, shares in Canbud Distribution Corporation (CSE: CBDX | FSE: CD0) appear poised to move higher as it executes on its three-pronged business model. Canbud is a science and technology company that concentrates its attention on the Hea...
Featured Submission | February 1, 2021 |

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Shares of Regeneron Pharmaceuticals rose to a new 52-week high price after the company reported it has identified hundreds of virus-neutralizing antibodies and plans to initiate large-scale manufacturing by mid-April of a multi-antibody therapy to treat coronavirus. ...
Streetwise Reports | March 18, 2020 |

An Emerging Medical Market Play with Great Opportunity

(Image via Bioasis Technologies Inc.) Biopharmaceutical Company Bioasis Technologies Inc. ( TSX-V: BTI , OTCQB: BIOAF , Forum ) is developing its proprietary xB 3TM platform technology to deliver therapeutics across the blood brain barrier (BBB) and int...
Stockhouse Editorial | July 28, 2020 |

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. Clinical-stage biopharmaceutical company Protago...
Streetwise Reports | December 5, 2019 |

Biopharma's Technology Could Render Drug Suitable for COVID-19 Treatment

How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report. In an April 7 research note, ROTH Capital Partners analyst Jonathan Aschoff discussed the potential of app...
Streetwise Reports | April 9, 2020 |

Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment

The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report. In a June 16 research note, ROTH Capital Partners analyst Scott Henry reported that Beyond Air Inc. (XAIR:NASDAQ) enrolled the first patient in its U.S. clin...
Streetwise Reports | June 18, 2020 |

Unique Value-Added Antiviral Vaccine Technology Platform

(Click to play video.) Founded in 2018 to improve on protein haptenization and leverage previous vaccine development in the field, Vancouver, BC-based BioVaxys Technology Corp . ( CSE.BIOV , OTCQB: BVAX , Forum ) is a clinical stage biotechnology company that...
Dave Jackson | September 14, 2021 |
1 2 3 4 5 6 7 8 9